S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
10 Best Airline Stocks to Buy
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Stock market today: Wall Street listless early ahead of new labor market data
What is a Growth Stock Mutual Fund?
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Ollie’s Bargain Outlet Goes On Sale 
Will MicroVision Maintain Its Momentum After the Short Squeeze?
The Real Problem With "Made in America" Lithium (Ad)
Campbell Soup Company Leads Staples Stocks Into The Buy Zone
Apple Partnership Strengthens Unity Software's Investment Appeal
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
10 Best Airline Stocks to Buy
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Stock market today: Wall Street listless early ahead of new labor market data
What is a Growth Stock Mutual Fund?
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Ollie’s Bargain Outlet Goes On Sale 
Will MicroVision Maintain Its Momentum After the Short Squeeze?
The Real Problem With "Made in America" Lithium (Ad)
Campbell Soup Company Leads Staples Stocks Into The Buy Zone
Apple Partnership Strengthens Unity Software's Investment Appeal
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
10 Best Airline Stocks to Buy
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Stock market today: Wall Street listless early ahead of new labor market data
What is a Growth Stock Mutual Fund?
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Ollie’s Bargain Outlet Goes On Sale 
Will MicroVision Maintain Its Momentum After the Short Squeeze?
The Real Problem With "Made in America" Lithium (Ad)
Campbell Soup Company Leads Staples Stocks Into The Buy Zone
Apple Partnership Strengthens Unity Software's Investment Appeal
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
10 Best Airline Stocks to Buy
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Stock market today: Wall Street listless early ahead of new labor market data
What is a Growth Stock Mutual Fund?
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Ollie’s Bargain Outlet Goes On Sale 
Will MicroVision Maintain Its Momentum After the Short Squeeze?
The Real Problem With "Made in America" Lithium (Ad)
Campbell Soup Company Leads Staples Stocks Into The Buy Zone
Apple Partnership Strengthens Unity Software's Investment Appeal
NASDAQ:TCRR

TCR2 Therapeutics (TCRR) Price Target & Analyst Ratings

$1.48
-0.09 (-5.73%)
(As of 06/1/2023)
Compare
Today's Range
$1.48
$1.63
50-Day Range
$1.43
$1.98
52-Week Range
$0.82
$3.88
Volume
3.91 million shs
Average Volume
494,777 shs
Market Capitalization
$58.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.91

TCR2 Therapeutics Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 8 Analyst Ratings

Consensus Analyst Price Target

$4.91
232.05% Upside
High Prediction$13.00
Average Prediction$4.91
Low Prediction$1.68
TypeCurrent
6/8/22 to 6/8/23
1 Month Ago
5/9/22 to 5/9/23
3 Months Ago
3/10/22 to 3/10/23
1 Year Ago
6/8/21 to 6/8/22
Consensus Rating
Hold
Hold
Hold
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
5 Buy rating(s)
Hold
6 Hold rating(s)
6 Hold rating(s)
4 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$4.91$4.91$6.20$17.38
Predicted Upside232.05% Upside246.64% Upside369.30% Upside167.69% Upside
Get TCR2 Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for TCRR and its competitors with MarketBeat's FREE daily newsletter.


TCRR Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

TCRR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

TCR2 Therapeutics Stock vs. The Competition

TypeTCR2 TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.25
2.66
2.49
Consensus RatingHoldBuyHold
Predicted Upside232.05% Upside1,238.86% Upside228.69% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/24/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$20.00 ➝ $1.72+21.13%
3/23/2023Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral$2.18 ➝ $1.68+18.31%
3/23/2023EF Hutton Acquisition Co. I
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold$2.00+35.13%
3/9/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$18.00 ➝ $3.00+93.55%
3/7/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$8.00 ➝ $3.00+87.50%
3/7/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Burns
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
1/5/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$8.00 ➝ $10.00+817.42%
8/8/2022Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
T. Butler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
(Data available from 6/8/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












TCRR Price Target - Frequently Asked Questions

What is TCR2 Therapeutics's consensus rating and price target?

According to the issued ratings of 8 analysts in the last year, the consensus rating for TCR2 Therapeutics stock is Hold based on the current 6 hold ratings and 2 buy ratings for TCRR. The average twelve-month price prediction for TCR2 Therapeutics is $4.91 with a high price target of $13.00 and a low price target of $1.68. Learn more on TCRR's analyst rating history.

Do Wall Street analysts like TCR2 Therapeutics more than its competitors?

Analysts like TCR2 Therapeutics less than other Medical companies. The consensus rating for TCR2 Therapeutics is Hold while the average consensus rating for medical companies is Buy. Learn more on how TCRR compares to other companies.

Is TCR2 Therapeutics being downgraded by Wall Street analysts?

Over the previous 90 days, TCR2 Therapeutics's stock had 1 downgrade by analysts.

Does TCR2 Therapeutics's stock price have much upside?

According to analysts, TCR2 Therapeutics's stock has a predicted upside of 246.64% based on their 12-month price targets.

What analysts cover TCR2 Therapeutics?

TCR2 Therapeutics has been rated by EF Hutton Acquisition Co. I, Mizuho, and Wedbush in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:TCRR) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -